Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $0.28, $0.57 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $70.5 million versus the consensus estimate of $66.32 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2024 EPS of (~$1.05), versus the consensus of ($0.95). Fulgent Genetics, Inc. sees FY2024 revenue of ~$280 million, versus the consensus of $294.2 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.